Clinical Trials Logo

Nonalcoholic Fatty Liver Disease clinical trials

View clinical trials related to Nonalcoholic Fatty Liver Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04766476 Terminated - Clinical trials for Nonalcoholic Fatty Liver Disease

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Start date: February 24, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.

NCT ID: NCT02029586 Terminated - Clinical trials for Nonalcoholic Fatty Liver Disease

Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.

NCT ID: NCT01355575 Terminated - NAFLD Clinical Trials

Rifaximin in Fatty Liver Disease

RiFL
Start date: May 2011
Phase: Phase 4
Study type: Interventional

TITLE Rifaximin in Fatty Liver Disease (RiFL) DESIGN Open-label pilot study HYPOTHESIS Reduction in gut flora by the antibiotic Rifaximin reduces hepatic inflammation in Non-Alcoholic Steatohepatitis (NASH). AIMS To provide proof-of-concept data on the therapeutic potential of gut flora modification in NASH OUTCOME MEASURES Primary: • Change in serum ALT from baseline by 25 IU/L or to within normal range after 6 weeks of Rifaximin therapy Secondary: - Change in intrahepatic triglyceride, estimated by in vivo proton magnetic resonance spectroscopy (1H MRS) - Change in hepatic insulin resistance, estimated by the hyperinsulinaemic euglycaemic clamp - Changes to the faecal bacterial microbiome assessed by faecal DNA pyrosequencing and fluorescent in-situ hybridisation (FISH) - Differences in urinary metabolic profiles as assessed by high-resolution proton nuclear magnetic resonance spectroscopy POPULATION Patients with biopsy-confirmed non-alcoholic steatohepatitis and persistently raised serum aminotransferase levels TREATMENT The non-absorbable antibiotic Rifaximin DURATION This was an open-label study of Rifaximin (Normix, Alfa Wasserman S.p.A, Bologna, Italy) 400mg twice daily for six weeks followed by a further six weeks observation period during which patients received standard care.

NCT ID: NCT01244503 Terminated - Metabolic Syndrome Clinical Trials

Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to demonstrate that the ¹³C-Octanoate Breath Test (OBT) can be used as an aid, in conjunction with other clinical information and medical history, for evaluating disease severity and detecting NASH with a high probability.

NCT ID: NCT00637520 Terminated - Insulin Resistance Clinical Trials

Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study

Start date: July 2007
Phase: N/A
Study type: Observational

We hypothesize that insulin resistance is characteristic of nonalcoholic fatty liver disease as compared to age, gender, non-diabetic BMI-matched control subjects, both healthy and those with non-cirrhotic, non-steatotic liver disease.